Related Experiment Video

Updated: Jun 21, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

The role of m6A methylation in targeted therapy resistance in lung cancer

Huange Xue1, Yufei Ma2, Kaiwen Guan1

  • 1Department of Radiation Oncology, The First Affiliated Hospital of Xinxiang Medical University Xinxiang, Henan, China.

American Journal of Cancer Research
|July 15, 2024
PubMed

Insights

N6-methyladenosine (m6A) RNA modification plays a key role in lung cancer (LC) drug resistance. Understanding m6A function is crucial for overcoming targeted therapy resistance and preventing disease relapse in LC patients.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Targeted therapies improve lung cancer (LC) outcomes but acquired drug resistance and relapse remain significant challenges.
  • Epigenetic mechanisms, particularly RNA modifications, are increasingly recognized as drivers of acquired drug resistance in cancer.
  • N6-methyladenosine (m6A) is a prevalent RNA modification influencing RNA fate and cancer progression.

Purpose of the Study:

  • To review and summarize the current understanding of N6-methyladenosine (m6A) RNA methylation's role in the development of targeted therapy resistance in lung cancer (LC).

Main Methods:

  • Literature review and synthesis of existing research on m6A RNA methylation in lung cancer.
  • Analysis of studies investigating the functional impact of m6A on cancer cell behavior and drug response.

Main Results:

  • N6-methyladenosine (m6A) modification is implicated in modulating lung cancer cell growth, invasion, and resistance to targeted therapies.
  • m6A regulates key cellular processes including RNA stability, splicing, transcription, translation, and degradation, contributing to therapeutic challenges.

Conclusions:

  • N6-methyladenosine (m6A) is a critical epigenetic regulator in lung cancer (LC) progression and acquired resistance to targeted treatments.
  • Further research into m6A mechanisms may reveal novel therapeutic strategies to overcome drug resistance and improve patient outcomes in LC.
Keywords:
epidermal growth factor receptor tyrosine kinase inhibitorslung cancerm6A methylationtargeted therapy resistance

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

10.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.0K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
174
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K